In vitro Assessment of Gentian Violet Anti-Candida Activity

• Type: Article in International Scientific Journal
• Date: 2012

Authors

Gomes de Elvas, AR (Author) Other; Palmeira de Oliveira, A (Author) Other; Gaspar, C (Author) Other; Gouveia, P (Author) Other; Palmeira de Oliveira, R (Author) Other; pina-vaz, c (Author) FMUP; rodrigues, ag (Author) FMUP; Martinez de Oliveira, J (Author) Other

Journal

Title: Gynecologic and Obstetric Investigation

Vol. 74

Pages: 120-124

ISSN: 0378-7346

Publisher: Karger

Indexing

ISI Web of Knowledge - 6 Citations

Scopus - 6 Citations

Other information

Authenticus ID: P-002-FD0

DOI: 10.1159/000338899

Abstract (EN): Background/Aim:Recurrent vulvovaginal candidosis (RVVC) needs alternative therapeutic approaches. Gentian violet (GeV) has been traditionally used to treat mucocutaneous candidosis. The aim of the present study was to evaluate the in vitro activity of GeV against Candida spp. and contribute to clarify the mechanism of action, supporting its clinical therapeutic use. Methods: Seventeen clinical Candida isolates from RVVC and one C. albicans type collection (ATCC 10231) were studied; the antifungal activity of GeV was evaluated according to the CLSI M27-A3 protocol. To elucidate its mechanism of action, cells were stained with propidium iodide and afterwards analyzed by flow cytometer. Results: GeV showed a fungicidal activity against most Candida spp. C. albicans and C. tropicalis were the most susceptible species. Minimal lethal concentrations were similar to minimal inhibitory concentrations for most tested strains. The fungicidal effect was not related to a primary lesion of the cytoplasmic membrane. Conclusion: In accordance with our findings, GeV is a valuable potent fungicidal drug to be used topically, isolated or in combination with oral antifungal drugs, particularly in RVVC cases. Copyright (c) 20125. Karger AG, Basel

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 5